Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. Eli Lilly has advanced in the triple-digits ...

Eli Lilly's 3-step strategy to dominate the $95 billion obesity market

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
The American Journal of Managed Care

Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD

Preclinical data suggest a possible synergistic interaction between estrogen and GLP-1 signaling, explains Regina Castaneda, MD. Midlife weight gain is a persistent challenge for many women, but ...
Medscape

Tirzepatide as Effective in Women as in Men for Obesity-Related HFpEF

MINNEAPOLIS — The GLP-1 receptor agonist tirzepatide confers the same benefit in women as it does in men with obesity-related heart failure with preserved ejection fraction (HFpEF), according to a new ...